Trump congratulates Republicans after ‘big beautiful bill' passes House panel
President Trump sent kudos to House Republicans after they worked late Sunday evening and narrowly cleared a key hurdle to advance the 'big beautiful bill' that contains most of his legislative priorities.
'CONGRATULATIONS REPUBLICANS!!!' the president posted on Truth Social just before 1 a.m. on Monday. 'MAKE AMERICA GREAT AGAIN!!!'
The House Budget Committee, in an unusual late-night meeting on Sunday, voted 17-16 to advance the 'One Big Beautiful Bill Act,' which would extend Trump's 2017 tax cuts, boost funding for his immigration crackdown efforts and cut spending on some social programs. House members had spent several days last week haggling over nuances in the bill, including spending cuts and concerns over its impact on long-term debt.
Four Republicans who had sunk the vote to advance the proposal last week — Reps. Ralph Norman (S.C.), Chip Roy (Texas), Andrew Clyde (Ga.), and Josh Brecheen (Okla.) — voted present Sunday evening so the bill could move forward.
After the vote, Speaker Mike Johnson (R-La.) said the House will continue to work on details as the measure moves to the Rules Committee.
'There's a lot more work to do, we've always acknowledged that towards the end there will be more details to iron out, we have several more to take care of,' he told reporters.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
16 minutes ago
- Newsweek
Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Marjorie Taylor Greene has spoken out against a new COVID-19 vaccine being approved in the United States, saying the move is "not MAHA at all." Why It Matters Health Secretary Robert F. Kennedy Jr. is facing repeated backlash for some of his positions on health and medicine, including from people who would ordinarily support him. In May, prominent members of the Make America Great Again movement, including Nicole Shanahan, Kennedy's former presidential running mate, and media personality Laura Loomer, spoke out against Kennedy Jr.'s pick for U.S. Surgeon General Casey Means. In March, Kennedy Jr. sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. AP What To Know The U.S. Food and Drug Administration (FDA) gave the green light for mNEXSPIKE (mRNA-1283), Moderna's new lower-dose COVID-19 vaccine, on May 31. Greene, the U.S. representative for Georgia's 14th congressional district, shared Moderna's post about the recent approval with the caption: "Not MAHA at all!!! Unreal." Not MAHA at all!!! Unreal. — Rep. Marjorie Taylor Greene🇺🇸 (@RepMTG) June 1, 2025 She was referring to Kennedy Jr.'s movement Make America Healthy Again, whose mission is to "aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases." Newsweek has contacted the United States Department of Health and Human Services outside of office hours, via email, for comment. The new vaccine is set to be used for adults 65 or older or people between the ages of 12 and 64 with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). Approval for the jab is "based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial which enrolled approximately 11,400 participants aged 12 years and older," Moderna says. It comes after Kennedy Jr. announced that the CDC is no longer encouraging COVID-19 vaccines for pregnant women and healthy children, marking a shift in federal public health guidance. What People Are Saying Chief Executive Officer of Moderna Stéphane Bancel said in a statement: "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." Kennedy Jr. said about the new CDC guidance: "I couldn't be more pleased to announce that as of today the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." What Happens Next The new vaccine is expected to be ready for those eligible to take it in time for the 2025-2026 respiratory virus season. You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (an mRNA vaccine for preventing COVID-19) or any Moderna COVID-19 vaccine or to any ingredient in these vaccines, the company warns.
Wall Street Journal
24 minutes ago
- Wall Street Journal
Podcast: Trump's Plan B After Trade Court Setback
Last week, an obscure trade court dropped a bombshell ruling: President Trump didn't have the authority to issue sweeping tariffs under a 1977 law. The government has appealed the court's decision. WSJ's James Fanelli and Gavin Bade dig into the ruling and what it could mean for the future of Trump's trade agenda. Annie Minoff hosts. 🎧 Listen here to The Journal podcast.
Wall Street Journal
28 minutes ago
- Wall Street Journal
Global Markets, U.S. Futures Lower on Trade Tensions
Global stocks and U.S. futures started the new month lower after President Trump threatened to double tariffs on steel and aluminum, and trade tensions escalated between China and the U.S. Late Friday, Trump said he would increase tariffs on steel and aluminum up to 50%, starting Wednesday. The president also accused China of breaking a trade truce agreed in mid-May, which China has denied.
